// App-Quantinova.ai

P691 : Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52

Researchers

Presenter

  • D Garca-Olmo

Principal Investigators

  • J Pans

  • N Brayshaw

  • M P Richard

  • C Agboton

Medical Centers

  • Faculty of Medicine, Autonomous University of Madrid, Department of Surgery, Madrid, Spain

  • Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Gastroenterology Department, Barcelona, Spain

  • Takeda Pharmaceuticals International, London, UK

  • TiGenix S.A.U., Tres Cantos, Madrid, Spain

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

Locations

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CX601

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved